Literature DB >> 25446622

Cerebral ABC transporter-common mechanisms may modulate neurodegenerative diseases and depression in elderly subjects.

Jens Pahnke1, Christina Fröhlich2, Kristin Paarmann3, Markus Krohn3, Nenad Bogdanovic4, Dag Årsland5, Bengt Winblad6.   

Abstract

In elderly subjects, depression and dementia often coincide but the actual reason is currently unknown. Does a causal link exist or is it just a reactive effect of the knowledge to suffer from dementia? The ABC transporter superfamily may represent a causal link between these mental disorders. Since the transporters ABCB1 and ABCC1 have been discovered as major β-amyloid-exporting molecules at the blood-brain barrier and ABCC1 was found to be directly activated by St. John's wort (SJW), depression and dementia certainly share an important pathophysiologic link. It was recognized that herbal anti-depressant formulations made from SJW are at least as effective for the treatment of unipolar depression in old age as classical pharmacotherapy, while having fewer side effects (Cochrane reports, 2008). SJW is known to activate various metabolizing and transport systems in the body, with cytochrome P450 enzymes and ABC transporters being most important. Does the treatment of depression in elderly subjects using pharmacological compounds or phytomedical extracts target a mechanism that also accounts for peptide storage in Alzheimer's disease and perhaps other proteopathies of the brain? In this review we summarize recent data that point to a common mechanism and present the first promising causal treatment results of demented elderly subjects with distinct SJW extracts. Insufficient trans-barrier clearance may indeed present a common problem in all the proteopathies of the brain where toxic peptides are deposited in a location-specific manner. Thus, activation of efflux molecules holds promise for future treatment of this large group of devastating disorders.
Copyright © 2015 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABC transporter; Alzheimer's disease; Blood–brain barrier; Dementia; Depression; St. John's wort

Mesh:

Substances:

Year:  2014        PMID: 25446622     DOI: 10.1016/j.arcmed.2014.10.010

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  12 in total

Review 1.  Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Xin Fang
Journal:  Metab Brain Dis       Date:  2018-04-22       Impact factor: 3.584

2.  Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-D-aspartate glutamate receptor antibodies in dementias.

Authors:  Mandy Busse; Ralf Kunschmann; Henrik Dobrowolny; Jessica Hoffmann; Bernhard Bogerts; Johann Steiner; Thomas Frodl; Stefan Busse
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-08       Impact factor: 5.270

3.  Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET.

Authors:  Viktoria Zoufal; Thomas Wanek; Markus Krohn; Severin Mairinger; Thomas Filip; Michael Sauberer; Johann Stanek; Thomas Pekar; Martin Bauer; Jens Pahnke; Oliver Langer
Journal:  J Cereb Blood Flow Metab       Date:  2018-10-24       Impact factor: 6.200

4.  The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM.

Authors:  Steffen E Storck; Anika M S Hartz; Jessica Bernard; Andrea Wolf; André Kachlmeier; Anne Mahringer; Sascha Weggen; Jens Pahnke; Claus U Pietrzik
Journal:  Brain Behav Immun       Date:  2018-07-21       Impact factor: 7.217

Review 5.  The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice.

Authors:  Gargi Banerjee; Roxana Carare; Charlotte Cordonnier; Steven M Greenberg; Julie A Schneider; Eric E Smith; Mark van Buchem; Jeroen van der Grond; Marcel M Verbeek; David J Werring
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-08-26       Impact factor: 10.154

6.  Anti-Inflammatory Activity of A Polyphenolic Extract from Arabidopsis thaliana in In Vitro and In Vivo Models of Alzheimer's Disease.

Authors:  Roberto Mattioli; Antonio Francioso; Maria d'Erme; Maurizio Trovato; Patrizia Mancini; Lucia Piacentini; Assunta Maria Casale; Ludger Wessjohann; Roberta Gazzino; Paolo Costantino; Luciana Mosca
Journal:  Int J Mol Sci       Date:  2019-02-07       Impact factor: 5.923

Review 7.  The Interplay of ABC Transporters in Aβ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer's Disease.

Authors:  Tapan Behl; Ishnoor Kaur; Aayush Sehgal; Arun Kumar; Md Sahab Uddin; Simona Bungau
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

8.  Revisiting rodent models: Octodon degus as Alzheimer's disease model?

Authors:  Johannes Steffen; Markus Krohn; Kristin Paarmann; Christina Schwitlick; Thomas Brüning; Rita Marreiros; Andreas Müller-Schiffmann; Carsten Korth; Katharina Braun; Jens Pahnke
Journal:  Acta Neuropathol Commun       Date:  2016-08-26       Impact factor: 7.801

9.  Sideritis spp. Extracts Enhance Memory and Learning in Alzheimer's β-Amyloidosis Mouse Models and Aged C57Bl/6 Mice.

Authors:  Jacqueline Hofrichter; Markus Krohn; Toni Schumacher; Cathleen Lange; Bjöorn Feistel; Bernd Walbroel; Jens Pahnke
Journal:  J Alzheimers Dis       Date:  2016-05-31       Impact factor: 4.472

10.  Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches.

Authors:  Markus Krohn; Thomas Wanek; Marie-Claude Menet; Andreas Noack; Xavier Declèves; Oliver Langer; Wolfgang Löscher; Jens Pahnke
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2018-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.